In Brief: Somerset's Eldepryl
Executive Summary
Somerset's Eldepryl: Capsules will replace the tablet formulation of the Alzheimer's treatment selegiline following May 17 approval of the new form. The capsules will be available within the next two weeks at the same dosage strength and price as the tablets. "The capsule will protect patients from confusing Eldepryl with unsafe counterfeit copies" that have appeared in the U.S., the company says. The capsule will also protect Eldepryl from generic competition; orphan drug exclusivity for Eldepryl expires June 5. Currently filed ANDAs for the generic tablet formulation will not be therapeutically equivalent to the capsule...